상세 보기
Clinical experience with tumor necrosis factor blockers in Korean rheumatoid arthritis patients
- Hur,Jin-Wuk;
- Choi,Chan-Bum;
- Bae,Sang-Cheol
Citations
SCOPUS
4초록
Tumor necrosis factor (TNF) blockers have become an important treatment in rheumatoid arthritis (RA) with its proven effectiveness. But it is not universally effective in all patients and it comes with a relatively high economic burden. We should use them effectively. Advances in pharmacoeconomics and pharmacogenetics may be able to help us reach this goal. This article will review our clinical experience of biological agents to treat RA at Hanyang University in Korea, with emphasis on the current therapies targeting TNF and the rational use of theses agents in RA.
키워드
Etanercept; Infliximab; Rheumatoid arthritis; TNF-��; abatacept; adalimumab; antihistaminic agent; C reactive protein; cyclosporin; disease modifying antirheumatic drug; etanercept; golimumab; hydroxychloroquine; infliximab; leflunomide; methotrexate; monoclonal antibody; nonsteroid antiinflammatory agent; placebo; rituximab; salazosulfapyridine; steroid; tumor necrosis factor alpha; tumor necrosis factor derivative; unclassified drug; article; clinical trial; cost effectiveness analysis; drug dose regimen; drug efficacy; drug eruption; dyspnea; economic aspect; erythema; erythrocyte sedimentation rate; face edema; headache; human; hypertension; hypotension; injection site reaction; Korea; lupus like syndrome; nausea; pharmacogenetics; pneumonia; priority journal; pruritus; rheumatoid arthritis; single nucleotide polymorphism; thorax pain; tuberculosis; upper respiratory tract infection; vomiting
- 제목
- Clinical experience with tumor necrosis factor blockers in Korean rheumatoid arthritis patients
- 저자
- Hur,Jin-Wuk; Choi,Chan-Bum; Bae,Sang-Cheol
- 발행일
- 2006-08
- 유형
- Article
- 권
- 9
- 호
- 2
- 페이지
- 146 ~ 149